

Supplementary Materials for

Fault Diagnosis Engineering of Digital Circuits Can Identify Vulnerable Molecules in Complex Cellular Pathways

Ali Abdi, Mehdi Baradaran Tahoori, Effat S. Emamian*

*To whom correspondence should be addressed. E-mail: emame@ATNTUSA.com

Published 21 October 2008, *Sci. Signal.* **1**, ra10 (2008)

DOI: 10.1126/scisignal.2000008

This PDF file includes:

Methods

Fig. S1. Intermolecular interactions of the p53 network.

Fig. S2. The digital electronic p53 circuit.

Fig. S3. Intermolecular interactions of the CREB network.

Fig. S4. The digital electronic CREB circuit.

Fig. S5. A typical path between an erroneous node to primary outputs and flip-flops.

Fig. S6. A simple path between an erroneous input to a primary output.

Fig. S7. Applying error propagation rules for a reconverging path.

Table S1. Logic equations of the caspase3–FKHR network.

Table S2. Logic equations of the p53 network.

Table S3. Logic equations of the CREB network.

Table S4. Computing probability at the output of a gate in terms of its inputs.

References

Supplementary Materials

Supplementary Methods

Vulnerability assessment algorithm

Here we summarize our molecular vulnerability assessment algorithm, through which the vulnerability of a cellular signaling network to the dysfunction of its components can be calculated. The details of each step are explained in the Method Section.

1. Specify the inputs nodes (such as ligands, receptors, secondary messengers, etc.) and the output nodes (such as different transcription factors relevant to the input signal), as well as the intermediate molecules that allow the input signals to propagate from the inputs to the outputs. Then specify the type of the interactions among the molecules (stimulatory or inhibitory), using the existing literature.
2. Use Rule #1 and Rule #2, to derive a binary logic equation for every intermediate molecule and the output molecules, using the interactions specified in Step 1.
3. Construct the digital circuit of the network from the binary logic equations of Step 2, using the AND, OR, NOT and BUFFER digital circuit elements.
4. Identify the feedback paths of the digital circuit of Step 3, using the depth-first search (DFS) algorithm. If there is no feedback path, proceed directly to the next step.
5. Finally, apply the EPP algorithm to the circuit obtained in the previous step, to calculate the vulnerability levels of all the input and intermediate nodes (the vulnerability of the output node is always 1, since if the output node is dysfunctional, the network will not operate efficiently anyway).

Deriving the logic equations

The logic equation of each molecule is a symbolic Boolean expression that shows how the activity of the molecule is regulated by its inputs. Using Rule #1 and Rule #2, a binary logic equation for each intermediate molecule and the output molecule were obtained, in terms of the input stimulators and inhibitors. These two rules are devised based on the known physiological mechanisms that different regulators employ to control the activity of signaling molecules. Rule #1 applies the Boolean OR of activating inputs to a signaling network. Rule #2 applies the Boolean AND of inverted inhibitory inputs to the network. In the derived equations for the networks, ' , + and \times stand for the binary logic operations NOT, OR and AND, respectively.

Constructing the digital circuits

To obtain the digital circuit schematic of a set of logic equations for a particular network, the ' , + and \times operations were represented in the circuit by NOT, OR and AND circuit components, respectively. Equations of the form $X = Y$, where X and Y are two different molecules and X is activated by Y , were implemented using the BUFFER circuit component.

Table S1. Logic equations of the caspase3-FKHR network. Each logic equation specifies the input signals to a molecule using the logic operations ', + and \times , which represent NOT, OR and AND, respectively. These equations are used to generate the digital electronic caspase3-FKHR circuit (Fig. 2B).

Molecule	Logic equation
AKT	$AKT = EGFR + Insulin$
Caspase3	$Caspase3 = AKT' \times (Caspase8 + JNK1 + MK2)$
Caspase8	$Caspase8 = cFLIP_L' \times (ComplexII + ERK)$
cFLIP _L	$cFLIP_L = NF\kappa B$
ComplexI	$ComplexI = TNF$
ComplexII	$ComplexII = TNF + ComplexI$
EGFR	$EGFR = EGF$
ERK	$ERK = MEK$
FKHR	$FKHR = AKT$
IKK	$IKK = ComplexI$
IRS1	$IRS1 = Insulin$
JNK1	$JNK1 = MKK7$
MEK	$MEK = EGFR + IRS1$
MEKK1ASK1	$MEKK1ASK1 = ComplexI$
MK2	$MK2 = p38$
MKK3	$MKK3 = MEKK1ASK1$
MKK7	$MKK7 = MEKK1ASK1$
NF κ B	$NF\kappa B = IKK$
P38	$p38 = MKK3$


Abl to Dok, Abl to p53^{43,83,104}, Abl to Vav, AC2 to cAMP, AC5 to cAMP, AKT to CASPASE9, AKT to p53^{50,90,119,121,125,166}, APS to Vav, Ca²⁺ to AC5, Ca²⁺ to PKC, cAMP to PKA, CASPASE3 to PIP5K, CASPASE3 to PP2A^{72,117}, CASPASE3 to PTEN^{26,147}, CASPASE8 to CASPASE3^{18,38,84,130}, CASPASE9 to CASPASE3^{78,103,128}, Cdc42 to PAK, DAG to PKC, Dok to RasGAP, Gab1 to PI3K, Grb10 to PI3K, Grb2 to Gab1, Grb2 to Vav, ILK to AKT, Insulin to IR, IP3 to IP3R, IP3R to Ca²⁺ ¹³⁹, IR to Grb10, IR to IRS1, IR to IRS2, IRS1 to Grb2, IRS1 to NCK, IRS1 to PI3K, IRS2 to PI3K, JIP to JNK, JNK to IRS1, JNK to JIP, JNK to p53, NCK to Abl, NCK to PAK, PAK to Abl, PDGF to PDGFR, PDGFR to APS, PDGFR to PLC γ , PDGFR to SHP2, PDK1 to AKT, PDK1 to PKC, PI3K to PIP3, PIP2 to AKT, PIP2 to CASPASE3, PIP2 to CASPASE8^{94,112}, PIP2 to CASPASE9, PIP2 to PMCA, PIP2 to RyR, PIP3 to AKT, PIP3 to ILK, PIP3 to PDK1, PIP3 to PKC, PIP3 to Vav, PIP3K to PIP2, PIP5K to PIP2, PKA to IP3R, PKA to p53, PKA to PLC β , PKA to PLC γ , PKA to PMCA, PKC to Abl, PKC to AC2, PKC to AC5, PKC to IRS1, PKC to PLC β , PKC to PMCA, PKC to SHP2, PLC β to DAG, PLC β to IP3, PLC β to PIP2, PLC γ to DAG, PLC γ to IP3, PLC γ to PIP2, PMCA to Ca²⁺ ¹⁰⁵, PP2A to AKT^{11,98,151}, PTEN to PIP3^{77,110}, Rac to PAK, RasGAP to AKT, Rho to PIP5K, Rho to ROCK, Rock to JIP, RyR to Ca²⁺ ⁵⁹, SHP2 to Gab1, SHP2 to Grb2, SHP2 to PI3K, Vav to Cdc42, Vav to Rac, Vav to Rho

Fig. S1. Intermolecular interactions of the p53 network. This network (Fig. 3A) includes the above 94 interactions, listed alphabetically, according to the name of “source” molecules. At least one representative reference from the national library of medicine (Pub Med) is listed for each individual interaction. These references are listed at the end of the Supplementary Materials.

Table S2. Logic equations of the p53 network. Each logic equation specifies the input signals to a molecule using the logic operations ‘, + and \times , which represent NOT, OR and AND, respectively. These equations are used to generate the digital p53 circuit (Fig. S2).

Molecule	Logic equation
Abl	Abl=NCK+PKC+PAK
AC2	AC2=PKC
AC5	AC5=(Ca ²⁺)’ \times PKC
APS	APS=PDGFR
Ca ²⁺	Ca ²⁺ =PMCA’ \times (IP3R+RyR)
cAMP	cAMP=AC2+AC5
CASPASE3	CASPASE3=PIP2’ \times (CASPASE8+CASPASE9)

CASPASE8	CASPASE8=PIP2'
CASPASE9	CASPASE9=PIP2'×AKT'
Cdc42	Cdc42=Vav
DAG	DAG=PLCβ+PLCγ
Dok	Dok=Abl
Gab1	Gab1=SHP2'×Grb2
Grb2	Grb2=IRS1+SHP2
Grb10	Grb10=IR
ILK	ILK=PIP3
IP3	IP3=PLCβ+PLCγ
IP3R	IP3R=PKA'×IP3
IR	IR=Insulin
IRS1	IRS1=JNK'×PKC'×IR
IRS2	IRS2=IR
JIP	JIP=ROCK+JNK
JNK	JNK=JIP'
NCK	NCK=IRS1
p53	p53=AKT'×(Abl+PKA+JNK)
PAK	PAK=Cdc42+NCK+Rac
PDK1	PDK1=PIP3
PDGFR	PDGFR=PDGF
PI3K	PI3K=Gab1+Grb10+IRS1+IRS2+SHP2
PIP2	PIP2=PI3K'×PLCβ'×PLCγ'×PIP5K
PIP3	PIP3=PTEN'×PI3K
PIP5K	PIP5K=CASPASE3'×Rho
PKA	PKA=cAMP
AKT	AKT=PP2A'×(ILK+PDK1+PIP2+PIP3+RasGAP)
PKC	PKC=PDK1+PIP3+DAG+Ca ²⁺
PLCβ	PLCβ=PKA'×PKC'
PLCγ	PLCγ=PKA'×PDGFR
PMCA	PMCA=PKA'×PKC'×PIP2
PP2A	PP2A=CASPASE3'
PTEN	PTEN=CASPASE3'
Rac	Rac=Vav
RasGAP	RasGAP=Dok
Rho	Rho=Vav
ROCK	ROCK=Rho
RyR	RyR=PIP2
SHP2	SHP2=PDGFR+PKC
Vav	Vav=Abl+APS+Grb2+PIP3




5-HT1AR to Galphas, 5-HT1AR to Galphaz, 5-HT1AR to Gbetagamma, 5-HT2AR to Gbetagamma, 5-HT4R to Galphas, 5-HT4R to Gbetagamma, A1R to Galphai, A1R to Gbetagamma, A2AR to Galphas, A2AR to Galphas, A2AR to Gbetagamma, AC1 to cAMP, AC2 to cAMP, AC5 to cAMP, Ach to M1R, Ach to M2R, Ach to M4R, Adenosine to A1R, Adenosine to A2AR, AKT to GSK3, Ca²⁺ to AC5, Ca²⁺ to Calmodulin, Ca²⁺ to PKC, Calmodulin to AC1, Calmodulin to CaMKII, Calmodulin to CaMKIV, Calmodulin to CaMKK, Calmodulin to mGluR₇, Calmodulin to NMDAR, Calmodulin to PLC β , Calmodulin to PP2B, CaMKI to CREB, CaMKII to CREB, CaMKII to N-type CaCh, CaMKII to PP2A, CaMKIV to CREB, CaMKIV to CREM, CaMKK to AKT, CaMKK to CaMKI, CaMKK to CaMKIV, cAMP to PKA, CBP to cJun, cJun to CREB, CREM to CREB, D1R to Galphai, D1R to Galphas, D1R to Gbetagamma, D2R to Galphai, D2R to Galphaz, D2R to Gbetagamma, D3R to Galphai, D3R to Gbetagamma, D3R to Grb2, DAG to PKC, Dopamine to D1R, Dopamine to D2R, Dopamine to D3R, DOR to Galphai, DOR to Gbetagamma, Enkephalin to DOR, Enkephalin to KOR, Enkephalin to MOR, Enkephalin to NOR, GABA to GABABR, GABABR to Gbetagamma, Galphai to AC2, Galphai to AC5, Galphas to AC1, Galphas to AC2, Galphas to AC5, Galphaz to AC1, Galphaz to AC5, Gbetagamma to AC1, Gbetagamma to AC2, Gbetagamma to N-type CaCh, Gbetagamma to P/Q-type CaCh, Gbetagamma to PI3K, Gbetagamma to PLC β , Gbetagamma to RasGAP, Glutamate to mGluR₁, Glutamate to mGluR₇, Glutamate to NMDAR, Grb2 to SAM68, GSK3 to cJun, GSK3 to CREB, ILK to AKT, ILK to GSK3, KOR to Gbetagamma, M1R to Gbetagamma, M2R to Galphai, M2R to Gbetagamma, M4R to Galphai, M4R to Gbetagamma, mGluR₁ to Gbetagamma, mGluR₇ to Galphai, mGluR₇ to Gbetagamma, MOR to Gbetagamma, NMDAR to Ca²⁺ ⁸⁶, NMDAR to CaMKII, NMDAR to PLC γ , NOR to Gbetagamma, N-type CaCh to Ca²⁺ ¹⁵⁷, P/Q-type CaCh to Ca²⁺ ⁵³, PDK1 to AKT, PDK1 to PKC, PDK1 to RSK, PI3K to PIP2, PI3K to PIP3, PIP2 to AKT, PIP3 to AKT, PIP3 to ILK, PIP3 to PDK1, PIP3 to PKC, PKA to CaMKK, PKA to CBP, PKA to CREB, PKA to D1R, PKA to mGluR₇, PKA to NMDAR, PKA to P/Q-type CaCh, PKA to PLC β , PKA to PLC γ , PKC to AC2, PKC to AC5, PKC to GSK3, PKC to mGluR₁, PKC to mGluR₇, PKC to NMDAR, PKC to N-type CaCh, PKC to PLC β , PLC β to DAG, PLC β to PIP2, PLC γ to DAG, PLC γ to PIP2, PP2A to AKT, PP2A to CaMKI, PP2A to CaMKIV, PP2A to CREB, PP2A to GSK3, PP2A to NMDAR, PP2B to CaMKIV, PP2B to CREB, PP2B to NMDAR, RasGAP to AKT, RSK to CREB, SAM68 to CBP, Serotonin to 5-HT1AR, Serotonin to 5-HT2AR, Serotonin to 5-HT4R

Fig. S3. Intermolecular interactions of the CREB network. This network (Fig. 4A) includes 152 interactions, listed alphabetically according to the name of “*source*” molecules. At least one representative reference from the national library of medicine (Pub Med) is listed for each individual interaction. These references are listed at the end of the Supplementary Materials.

Table S3. Logic equations of the CREB network. Each logic equation specifies the input signals to a molecule using the logic operations $'$, $+$ and \times , which represent NOT, OR and AND, respectively. These equations are used to generate the digital electronic CREB circuit (Fig. S4).

Molecule	Logic equation
A1R	A1R=Adenosine
A2AR	A2AR=Adenosine
AC1	AC1=Gbetagamma $'$ \times Galphaz $'$ \times (Galphas+Calmodulin)
AC2	AC2=Galphai $'$ \times (Gbetagamma+Galphas+PKC)
AC5	AC5=Galphai $'$ \times Galphaz $'$ \times (Ca ²⁺) $'$ \times (PKC+Galphas)
PP2B	PP2B=Calmodulin
Ca ²⁺	Ca ²⁺ =NMDAR+N-typeCaCh+P/QtypeCaCh
Calmodulin	Calmodulin=Ca ²⁺
CaMKI	CaMKI=PP2A $'$ \times CaMKK
CaMKII	CaMKII=Calmodulin+NMDAR
CaMKIV	CaMKIV=PP2A $'$ \times PP2B $'$ \times (Calmodulin+CaMKK)
CaMKK	CaMKK=PKA $'$ \times Calmodulin
cAMP	cAMP=AC1+AC2+AC5
CBP	CBP=SAM68 $'$ \times PKA
cJun	cJun=GSK3 $'$ \times CBP
CREB	CREB=PP2A $'$ \times PP2B $'$ \times CREM $'$ \times (GSK3+PKA+cJun+RSK+CaMKII+CaMKIV+CaMKI)
CREM	CREM=CaMKIV
D1R	D1R=PKA $'$ \times Dopamine
D2R	D2R=Dopamine
D3R	D3R=Dopamine
DAG	DAG=PLC β +PLC γ
DOR	DOR=Enkephalin
5-HT1AR	5-HT1AR=Serotonin
5-HT2AR	5-HT2AR=Serotonin
5-HT4R	5-HT4R=Serotonin
GABABR	GABABR=GABA $'$
Galphai	Galphai=A1R+D1R+D2R+D3R+M4R+M2R+mGluR ₇ +DOR+KOR+MOR+NOR+5-HT1AR
Galphas	Galphas=A2AR+D1R+5-HT1AR+5-HT4R
Galphaz	Galphaz=D2R+5-HT1AR
Gbetagamma	Gbetagamma=A1R+A2AR+M1R+M4R+M2R+D1R+D2R+D3R+GABABR+mGluR ₁ +mGluR ₇ +DOR+KOR+MOR+NOR+5-HT1AR+5-HT2AR+5-HT4R
Grb2	Grb2=D3R
GSK3	GSK3=ILK $'$ \times AKT $'$ \times PKC $'$ \times PP2A
ILK	ILK=PIP3
KOR	KOR=Enkephalin
M1R	M1R=Ach

M2R	M2R=Ach
M4R	M4R=Ach
mGluR ₁	mGluR ₁ =PKC+Glutamate
mGluR ₇	mGluR ₇ =Calmodulin'×(PKC+PKA+Glutamate)
MOR	MOR=Enkephalin
NMDAR	NMDAR=PKC'×PP2A'×Calmodulin'×PP2B'×(PKA+Glutamate)
NOR	NOR=Enkephalin
N-type CaCh	N-typeCaCh=Gbetagamma'×(PKC+CaMKII)
PDK1	PDK1=PIP3
PI3K	PI3K=Gbetagamma
PIP2	PIP2=PI3K'×PLCβ'×PLCγ'
PIP3	PIP3=PI3K
PKA	PKA=cAMP
AKT	AKT=PP2A'×(RasGAP+ILK+PIP3+PDK1+PIP2+CaMKK)
PKC	PKC=PDK1+PIP3+DAG+Ca ²⁺
PLCβ	PLCβ=PKA'×PKC'×(Gbetagamma+Calmodulin)
PLCγ	PLCγ=PKA'×NMDAR
PP2A	PP2A=CaMKII'
P/Q type CaCh	P/QtypeCaCh=PKA'×Gbetagamma
RasGAP	RasGAP=Gbetagamma
RSK	RSK=PDK1
SAM68	SAM68=Grb2






Fig. S5. A typical path between an erroneous node to primary outputs and flip-flops.




Fig. S6. A simple path between an erroneous input to a primary output.




Fig. S7. Applying error propagation rules for a reconverging path.

Table S4. Computing probability at the output of a gate in terms of its inputs.

AND	$P_1(out) = \prod_{i=1}^n P_1(X_i)$ $P_a(out) = \prod_{i=1}^n [P_1(X_i) + P_a(X_i)] - P_1(out)$ $P_{\bar{a}}(out) = \prod_{i=1}^n [P_1(X_i) + P_{\bar{a}}(X_i)] - P_1(out)$ $P_0(out) = 1 - [P_1(out) + P_a(out) + P_{\bar{a}}(out)]$
OR	$P_0(out) = \prod_{i=1}^n P_0(X_i)$ $P_a(out) = \prod_{i=1}^n [P_0(X_i) + P_a(X_i)] - P_0(out)$ $P_{\bar{a}}(out) = \prod_{i=1}^n [P_0(X_i) + P_{\bar{a}}(X_i)] - P_0(out)$ $P_1(out) = 1 - [P_0(out) + P_a(out) + P_{\bar{a}}(out)]$
NOT	$P_0(out) = P_1(in), P_1(out) = P_0(in)$ $P_a(out) = P_{\bar{a}}(in), P_{\bar{a}}(out) = P_a(in)$

Supplementary References

1. Adler, V. *et al.* Conformation-dependent phosphorylation of p53. *Proc. Natl. Acad. Sci. U. S. A.* 94, 1686 (1997).
2. Alessi, D. R. *et al.* Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B α . *Curr. Biol.* 7, 261 (1997).
3. Alexander, S. P. *et al.* Guide to receptors and channels, 1st edition. *Br. J. Pharmacol.* 141, S1 (2004).
4. Araki, E. *et al.* Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. *Nature.* 372, 186 (1994).
5. Bagrodia, S. *et al.* Cdc42 and PAK-mediated signaling leads to Jun kinase and p38 mitogen-activated protein kinase activation. *J. Biol. Chem.* 270, 27995 (1996).
6. Bannister, A. J. *et al.* Stimulation of c-Jun activity by CBP: c-Jun residues Ser63/73 are required for CBP induced stimulation in vivo and CBP binding in vitro. *Oncogene.* 11, 2509 (1996).
7. Barr, A. J. & Manning, D. R. Agonist-independent activation of Gz by the 5-hydroxytryptamine_{1A} receptor co-expressed in *Spodoptera frugiperda* cells. Distinguishing inverse agonists from neutral antagonists. *J. Biol. Chem.* 272, 32979 (1998).
8. Bassermann, F. *et al.* Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway. *J. Biol. Chem.* 277, 12437 (2002).
9. Beom, S. *et al.* Comparative studies of molecular mechanisms of dopamine D2 and D3 receptors for the activation of extracellular signal-regulated kinase. *J. Biol. Chem.* 279, 28304 (2004).
10. Bernstein, G. *et al.* Reconstitution of agonist-stimulated phosphatidylinositol 4,5-bisphosphate hydrolysis using purified m1 muscarinic receptor, Gq/11, and phospholipase C- β 1. *J. Biol. Chem.* 267, 8081 (1992).
11. Bjornsti, M.-A. & Houghton, P. J. The tor pathway: A target for cancer therapy. *Nature Rev. Cancer.* 4, 335 (2004).
12. Bockaert, J. *et al.* Pharmacological characterization of 5-hydroxytryptamine₄ (5-HT₄) receptors positively coupled to adenylate cyclase in adult guinea pig hippocampal membranes: effect of substituted benzamide derivatives. *Mol. Pharmacol.* 37, 408 (1990).
13. Bonner, T. I. *et al.* Identification of a family of muscarinic acetylcholine receptor genes. *Science.* 237, 527 (1987).

14. Boronenkov, I. V. & Anderson, R. A. The sequence of phosphatidylinositol-4-phosphate 5-kinase defines a novel family of lipid kinases. *J. Biol. Chem.* 270, 2881 (1995).
15. Burgess, G. M. *et al.* The second messenger linking receptor activation to internal Ca release in liver. *Nature.* 309, 63 (1984).
16. Camps, M. *et al.* Isozyme-selective stimulation of phospholipase C-beta 2 by G protein beta gamma-subunits. *Nature.* 360, 684 (1993).
17. Cardone, M. H. *et al.* Regulation of cell death protease caspase-9 by phosphorylation. *Science.* 282, 1318 (1998).
18. Chipuk, J. E. *et al.* Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. *Science.* 303, 1010 (2004).
19. Chu, A. & Stefani, E. Phosphatidylinositol 4,5-bisphosphate-induced Ca²⁺ release from skeletal muscle sarcoplasmic reticulum terminal cisternal membranes. Ca²⁺ flux and single channel studies. *J. Biol. Chem.* 266, 7699 (1991).
20. Conn, P. J. & Sanders-Bush, E. Selective 5HT-2 antagonists inhibit serotonin stimulated phosphatidylinositol metabolism in cerebral cortex. *Neuropharmacology.* 23, 993 (1984).
21. Constantinescu, A. *et al.* cAMP-dependent protein kinase type I regulates ethanol-induced cAMP response element-mediated gene expression via activation of CREB-binding protein and inhibition of MAPK. *J. Biol. Chem.* 279, 43321 (2004).
22. Cooper, D. M. *et al.* Adenosine receptor-mediated inhibition of rat cerebral cortical adenylate cyclase by a GTP-dependent process. *Mol. Pharmacol.* 18, 598 (1981).
23. Crespo, P. *et al.* Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product. *Nature.* 385, 169 (1997).
24. Crespo, P. *et al.* Ras-dependent activation of MAP kinase pathway mediated by G-protein beta gamma subunits. *Nature.* 369, 418 (1994).
25. Cross, D. A. *et al.* Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. *Nature.* 378, 785 (1996).
26. Cully, M. *et al.* Beyond PTEN mutations: The PI3K pathway as an integrator of multiple inputs during tumorigenesis. *Nature Rev. Cancer.* 6, 184 (2006).
27. D'Ambrosio, C. *et al.* Hyperphosphorylation of JNK-interacting protein 1, a protein associated with Alzheimer disease. *Mol. Cell. Proteomics.* 5, 97 (2006).
28. De Vivo, M. & Maayani, S. Characterization of the 5-hydroxytryptamine_{1a} receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in guinea pig and rat hippocampal membranes. *J. Pharmacol. Exp. Ther.* 238, 248 (1986).

29. De Waard, M. *et al.* Direct binding of G-protein betagamma complex to voltage-dependent calcium channels. *Nature*. 385, 446 (1997).
30. Delcommenne, M. *et al.* Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. *Proc. Natl. Acad. Sci. U. S. A.* 95, 11211 (1998).
31. Deng, Y. *et al.* Growth factor receptor-binding protein 10 (Grb10) as a partner of phosphatidylinositol 3-kinase in metabolic insulin action. *J. Biol. Chem.* 278, 39311 (2003).
32. DeRemer, M. F. *et al.* Ca^{2+} -calmodulin-dependent protein kinases Ia and Ib from rat brain. II. Enzymatic characteristics and regulation of activities by phosphorylation and dephosphorylation. *J. Biol. Chem.* 267, 13466 (1992).
33. Dessauer, C. W. *et al.* Identification of a G α binding site on type V adenylyl cyclase. *J. Biol. Chem.* 273, 25831 (1998).
34. Dickens, M. *et al.* A cytoplasmic inhibitor of the JNK signal transduction pathway. *Science*. 277, 693 (1997).
35. Dutil, E. M. *et al.* Regulation of conventional protein kinase C isozymes by phosphoinositide-dependent kinase 1 (PDK-1). *Curr. Biol.* 8, 1366 (1999).
36. Edelman, A. M. *et al.* Multiple Ca^{2+} -calmodulin-dependent protein kinase kinases from rat brain. Purification, regulation by Ca^{2+} -calmodulin, and partial amino acid sequence. *J. Biol. Chem.* 271, 10806 (1996).
37. Enslen, H. *et al.* Characterization of Ca^{2+} /calmodulin-dependent protein kinase IV. Role in transcriptional regulation. *J. Biol. Chem.* 269, 15520 (1994).
38. Evan, G. I. & Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. *Nature*. 411, 342 (2001).
39. Feinstein, P. G. *et al.* Molecular cloning and characterization of a Ca^{2+} /calmodulin-insensitive adenylyl cyclase from rat brain. *Proc. Natl. Acad. Sci. U. S. A.* 88, 10173 (1991).
40. Fiol, C. J. *et al.* A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression. *J. Biol. Chem.* 269, 32187 (1995).
41. Foulkes, N. S. *et al.* CREM gene: use of alternative DNA-binding domains generates multiple antagonists of cAMP-induced transcription. *Cell*. 64, 739 (1991).
42. Fukunaga, K. *et al.* Decreased protein phosphatase 2A activity in hippocampal long-term potentiation. *J. Neurochem.* 74, 807 (2000).
43. Giancotti, F. G. & Ruoslahti, E. Integrin signaling. *Science*. 285, 1028 (1999).
44. Goode, N. *et al.* Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes. *J. Biol. Chem.* 267, 16878 (1992).

45. Grilli, M. *et al.* Pharmacological characterization of D1 and D2 dopamine receptors in rat limbocortical areas. II. Dorsal hippocampus. *Neurosci. Lett.* 87, 253 (1988).
46. Gurd, J. W. & Bissoon, N. The N-methyl-D-aspartate receptor subunits NR2A and NR2B bind to the SH2 domains of phospholipase C-gamma. *J. Neurochem.* 69, 623 (1997).
47. Hadari, Y. R. *et al.* Insulin and insulinomimetic agents induce activation of phosphatidylinositol 3'-kinase upon its association with pp185 (IRS-1) in intact rat livers. *J. Biol. Chem.* 267, 17483 (1992).
48. Hai, T. & Curran, T. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. *Proc. Natl. Acad. Sci. U. S. A.* 88, 3720 (1991).
49. Han, J. *et al.* Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. *Science.* 279, 558 (1998).
50. Harris, S. L. & Levine, A. J. The p53 pathway: Positive and negative feedback loops. *Oncogene.* 24, 2899 (2005).
51. Hess, S. D. *et al.* Cloning and functional characterization of human heteromeric N-methyl-D-aspartate receptors. *J. Pharmacol. Exp. Ther.* 278, 808 (1996).
52. Hilgemann, D. W. *et al.* The complex and intriguing lives of PIP2 with ion channels and transporters. *Sci. STKE.* 2001, RE19, (2001).
53. Hillman, D. *et al.* Localization of P-type calcium channels in the central nervous system. *Proc. Natl. Acad. Sci. U. S. A.* 88, 7076 (1991).
54. Holgado-Madruga, M. *et al.* A Grb2-associated docking protein in EGF- and insulin-receptor signalling. *Nature.* 379, 560 (1996).
55. Holland, S. J. *et al.* Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells. *EMBO. J.* 16, 3877 (1997).
56. Hong, W. *et al.* Physical and functional interaction between the transcriptional cofactor CBP and the KH domain protein Sam68. *Mol. Cancer. Res.* 1, 48 (2002).
57. Hongpaisan, J. *et al.* Calcium-dependent mitochondrial superoxide modulates nuclear CREB phosphorylation in hippocampal neurons. *Mol. Cell. Neurosci.* 24, 1103 (2003).
58. Hu, B. *et al.* A critical interplay between Ca²⁺ inhibition and activation by Mg²⁺ of AC5 revealed by mutants and chimeric constructs. *J. Biol. Chem.* 277, 33139 (2002).

59. Imagawa, T. *et al.* Purified ryanodine receptor from skeletal muscle sarcoplasmic reticulum is the Ca^{2+} -permeable pore of the calcium release channel. *J. Biol. Chem.* 262, 16636 (1988).
60. Ishikawa, Y. *et al.* Isolation and characterization of a novel cardiac adenylylcyclase cDNA. *J. Biol. Chem.* 267, 13553 (1992).
61. Jensen, C. J. *et al.* 90-kDa ribosomal S6 kinase is phosphorylated and activated by 3-phosphoinositide-dependent protein kinase-1. *J. Biol. Chem.* 274, 27168 (1999).
62. Kajikawa, Y. *et al.* GTP-binding protein beta gamma subunits mediate presynaptic calcium current inhibition by GABA(B) receptor. *Proc. Natl. Acad. Sci. U. S. A.* 98, 8054 (2001).
63. Kameshita, I. & Fujisawa, H. Autophosphorylation of calmodulin-dependent protein kinase IV from rat cerebral cortex. *J. Biochem. (Tokyo)*. 113, 583 (1993).
64. Kapoor, G. S. *et al.* Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma cells. *Mol. Cell. Biol.* 24, 823 (2003).
65. Kasahara, J. *et al.* Differential effects of a calcineurin inhibitor on glutamate-induced phosphorylation of Ca^{2+} /calmodulin-dependent protein kinases in cultured rat hippocampal neurons. *J. Biol. Chem.* 274, 9061 (1999).
66. Kaupmann, K. *et al.* Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. *Nature*. 386, 239 (1997).
67. Kawabe, J. *et al.* Differential activation of adenylyl cyclase by protein kinase C isoenzymes. *J. Biol. Chem.* 269, 16554 (1994).
68. Kazlauskas, A. & Cooper, J. A. Autophosphorylation of the PDGF receptor in the kinase insert region regulates interactions with cell proteins. *Cell*. 58, 1121 (1989).
69. Kim, U. H. *et al.* Phosphorylation of phospholipase C-gamma by cAMP-dependent protein kinase. *J. Biol. Chem.* 264, 20167 (1990).
70. Klee, C. B. *et al.* Calcineurin: a calcium- and calmodulin-binding protein of the nervous system. *Proc. Natl. Acad. Sci. U. S. A.* 76, 6270 (1980).
71. Kobilka, B. K. *et al.* An intronless gene encoding a potential member of the family of receptors coupled to guanine nucleotide regulatory proteins. *Nature*. 329, 75 (1987).
72. Kong, M. *et al.* The PP2A-associated protein alpha4 is an essential inhibitor of apoptosis. *Science*. 306, 695 (2004).
73. Kozasa, T. & Gilman, A. G. Purification of recombinant G proteins from Sf9 cells by hexahistidine tagging of associated subunits. Characterization of alpha 12 and inhibition of adenylyl cyclase by alpha z. *J. Biol. Chem.* 270, 1734 (1995).

74. Lee, C. H. *et al.* Nck associates with the SH2 domain-docking protein IRS-1 in insulin-stimulated cells. *Proc. Natl. Acad. Sci. U. S. A.* 90, 11713 (1994).
75. Leonard, A. S. & Hell, J. W. Cyclic AMP-dependent protein kinase and protein kinase C phosphorylate N-methyl-D-aspartate receptors at different sites. *J. Biol. Chem.* 272, 12107 (1997).
76. Leonard, A. S. *et al.* Regulation of calcium/calmodulin-dependent protein kinase II docking to N-methyl-D-aspartate receptors by calcium/calmodulin and alpha-actinin. *J. Biol. Chem.* 277, 48441 (2002).
77. Li, A. G. *et al.* Mechanistic insights into maintenance of high p53 acetylation by PTEN. *Mol Cell.* 23, 575 (2006).
78. Li, P. *et al.* Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. *Cell.* 91, 479 (1997).
79. Libert, F. *et al.* Selective amplification and cloning of four new members of the G protein-coupled receptor family. *Science.* 244, 569 (1989).
80. Lieberman, D. N. & Mody, I. Regulation of NMDA channel function by endogenous Ca^{2+} -dependent phosphatase. *Nature.* 369, 235 (1994).
81. Litosch, I. Protein kinase C inhibits the Ca^{2+} -dependent stimulation of phospholipase C-beta 1 in vitro. *Recept. Signal. Transduct.* 6, 87 (1997).
82. Liu, M. & Simon, M. I. Regulation by cAMP-dependent protein kinase of a G-protein-mediated phospholipase C. *Nature.* 382, 83 (1996).
83. Look, T. Oncogenic transcription factors in the human acute leukemias. *Science.* 278, 1059 (1997).
84. Lowe, S. W. *et al.* Intrinsic tumour suppression. *Nature.* 432, 307 (2004).
85. Lu, W. *et al.* Activation of Pak by membrane localization mediated by an SH3 domain from the adaptor protein Nck. *Curr. Biol.* 7, 85 (1997).
86. MacDermott, A. B. *et al.* NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones. *Nature.* 321, 519 (1986).
87. Madison, D. V. *et al.* Phorbol esters block a voltage-sensitive chloride current in hippocampal pyramidal cells. *Nature.* 321, 695 (1986).
88. Manser, E. *et al.* A brain serine/threonine protein kinase activated by Cdc42 and Rac1. *Nature.* 367, 40 (1994).
89. Masu, M. *et al.* Sequence and expression of a metabotropic glutamate receptor. *Nature.* 349, 760 (1991).
90. Matoba, S. *et al.* p53 regulates mitochondrial respiration. *Science.* 312, 1650 (2006).
91. Matsushita, M. & Nairn, A. C. Inhibition of the Ca^{2+} /calmodulin-dependent protein kinase I cascade by cAMP-dependent protein kinase. *J. Biol. Chem.* 274, 10086 (1999).

92. McCullar, J. S. *et al.* Calmodulin is a phospholipase C-beta interacting protein. *J. Biol. Chem.* 278, 33708 (2003).
93. Meisenhelder, J. *et al.* Phospholipase C-gamma is a substrate for the PDGF and EGF receptor protein-tyrosine kinases in vivo and in vitro. *Cell.* 57, 1109 (1989).
94. Mejillano, M. *et al.* Regulation of apoptosis by phosphatidylinositol 4,5-bisphosphate inhibition of caspases, and caspase inactivation of phosphatidylinositol phosphate 5-kinases. *J. Biol. Chem.* 276, 1865 (2001).
95. Miller, S. G. & Kennedy, M. B. Regulation of brain type II Ca^{2+} /calmodulin-dependent protein kinase by autophosphorylation: a Ca^{2+} -triggered molecular switch. *Cell.* 44, 861 (1986).
96. Moeschel, K. *et al.* Protein kinase C-zeta-induced phosphorylation of Ser318 in insulin receptor substrate-1 (IRS-1) attenuates the interaction with the insulin receptor and the tyrosine phosphorylation of IRS-1. *J. Biol. Chem.* 279, 25157 (2004).
97. Montminy, M. R. *et al.* Identification of a cyclic-AMP-responsive element within the rat somatostatin gene. *Proc. Natl. Acad. Sci. U. S. A.* 83, 6682 (1986).
98. Mora, A. *et al.* Lithium blocks the PKB and GSK3 dephosphorylation induced by ceramide through protein phosphatase-2A. *Cell. Signal.* 14, 557 (2002).
99. Mussig, K. *et al.* Shp2 is required for protein kinase C-dependent phosphorylation of serine 307 in insulin receptor substrate-1. *J. Biol. Chem.* 280, 32693 (2005).
100. Najib, S. & Sanchez-Margalet, V. Sam68 associates with the SH3 domains of Grb2 recruiting GAP to the Grb2-SOS complex in insulin receptor signaling. *J. Cell. Biochem.* 86, 99 (2002).
101. Nakagawa, O. *et al.* ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. *FEBS. Lett.* 392, 189 (1996).
102. Nakajima, Y. *et al.* A relationship between protein kinase C phosphorylation and calmodulin binding to the metabotropic glutamate receptor subtype 7. *J. Biol. Chem.* 274, 27573 (1999).
103. Nicholson, D. W. From bench to clinic with apoptosis-based therapeutic agents. *Nature.* 407, 810 (2000).
104. Nie, Y. *et al.* Stimulation of p53 DNA binding by c-Abl requires the p53 C terminus and tetramerization. *Mol. Cell. Biol.* 20, 741 (2000).
105. Niggli, V. *et al.* Acidic phospholipids, unsaturated fatty acids, and limited proteolysis mimic the effect of calmodulin on the purified erythrocyte Ca^{2+} -ATPase. *J. Biol. Chem.* 256, 8588 (1981).

106. Obadiah, J. *et al.* Adenylyl cyclase interaction with the D2 dopamine receptor family; differential coupling to Gi, Gz, and Gs. *Cell. Mol. Neurobiol.* 19, 653 (1999).
107. Olah, M. E. Identification of A2a adenosine receptor domains involved in selective coupling to Gs. Analysis of chimeric A1/A2a adenosine receptors. *J. Biol. Chem.* 272, 337 (1997).
108. Oldenhof, J. *et al.* SH3 ligands in the dopamine D3 receptor. *Cell. Signal.* 13, 411 (2001).
109. Olson, M. F. *et al.* Faciogenital dysplasia protein (FGD1) and Vav, two related proteins required for normal embryonic development, are upstream regulators of Rho GTPases. *Curr. Biol.* 6, 1628 (1997).
110. Persad, S. *et al.* Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. *Proc. Natl. Acad. Sci. U. S. A.* 97, 3207 (2000).
111. Ren, X. D. *et al.* Physical association of the small GTPase Rho with a 68-kDa phosphatidylinositol 4-phosphate 5-kinase in Swiss 3T3 cells. *Mol. Biol. Cell.* 7, 435 (1996).
112. Rich, T. *et al.* Defying death after DNA damage. *Nature.* 407, 777 (2000).
113. Roig, J. *et al.* Functional interaction between c-Abl and the p21-activated protein kinase gamma-PAK. *Proc. Natl. Acad. Sci. U. S. A.* 97, 14346 (2001).
114. Ross, C. A. *et al.* Three additional inositol 1,4,5-trisphosphate receptors: molecular cloning and differential localization in brain and peripheral tissues. *Proc. Natl. Acad. Sci. U. S. A.* 89, 4265 (1992).
115. Ross, E. M. *et al.* Reconstitution of hormone-sensitive adenylate cyclase activity with resolved components of the enzyme. *J. Biol. Chem.* 253, 6401 (1978).
116. Runnels, L. W. *et al.* The TRPM7 channel is inactivated by PIP(2) hydrolysis. *Nat. Cell. Biol.* 4, 329 (2002).
117. Santoro, M. F. *et al.* Regulation of protein phosphatase 2A activity by caspase-3 during apoptosis. *J. Biol. Chem.* 273, 13119 (1998).
118. Sato, M. *et al.* Altered agonist sensitivity and desensitization of neuronal mGluR1 responses in knock-in mice by a single amino acid substitution at the PKC phosphorylation site. *Eur. J. Neurosci.* 20, 947 (2004).
119. Sawyers, C. Targeted cancer therapy. *Nature.* 432, 294 (2004).
120. Schuebel, K. E. *et al.* Phosphorylation-dependent and constitutive activation of Rho proteins by wild-type and oncogenic Vav-2. *EMBO. J.* 17, 6608 (1999).
121. Shaw, R. J. & Cantley, L. C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. *Nature.* 441, 424 (2006).

122. Sheng, M. *et al.* CREB: a Ca^{2+} -regulated transcription factor phosphorylated by calmodulin-dependent kinases. *Science*. 252, 1427 (1991).
123. Sidhu, A. *et al.* D1 dopamine receptors can interact with both stimulatory and inhibitory guanine nucleotide binding proteins. *J. Neurochem.* 57, 1445 (1991).
124. Singh, S. S. *et al.* Activation of protein kinase C by phosphatidylinositol 3,4,5-trisphosphate. *Biochem. Biophys. Res. Commun.* 195, 104 (1993).
125. Skeen, J. E. *et al.* Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. *Cancer Cell*. 10, 269 (2006).
126. Skolnik, E. Y. *et al.* The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling. *EMBO. J.* 12, 1929 (1993).
127. Smith, J. M. *et al.* Activation of the Abl tyrosine kinase in vivo by Src homology 3 domains from the Src homology 2/Src homology 3 adaptor Nck. *J. Biol. Chem.* 274, 27956 (1999).
128. Soengas, M. S. *et al.* Apaf-1 and Caspase-9 in p53-dependent apoptosis and tumor inhibition. *Science*. 284, 156 (1999).
129. Sorensen, S. D. *et al.* Dissociation of protein kinase-mediated regulation of metabotropic glutamate receptor 7 (mGluR7) interactions with calmodulin and regulation of mGluR7 function. *Mol. Pharmacol.* 61, 1303 (2002).
130. Srinivasula, S. M. *et al.* Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. *Proc. Natl. Acad. Sci. U. S. A.* 93, 14486 (1997).
131. Stahl, M. L. *et al.* Sequence similarity of phospholipase C with the non-catalytic region of src. *Nature*. 332, 269 (1988).
132. Stephens, L. *et al.* A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein beta gamma subunits. *Cell*. 77, 83 (1994).
133. Stephens, L. *et al.* Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. *Science*. 279, 710 (1998).
134. Sugimoto, S. *et al.* Expression, purification, and characterization of SH2-containing protein tyrosine phosphatase, SH-PTP2. *J. Biol. Chem.* 268, 22771 (1993).
135. Sugiyama, H. *et al.* Glutamate receptor subtypes may be classified into two major categories: a study on *Xenopus* oocytes injected with rat brain mRNA. *Neuron*. 3, 129 (1990).

136. Sun, X. *et al.* Interaction between protein kinase C delta and the c-Abl tyrosine kinase in the cellular response to oxidative stress. *J. Biol. Chem.* 275, 7470 (2000).
137. Sun, X. J. *et al.* Expression and function of IRS-1 in insulin signal transmission. *J. Biol. Chem.* 267, 22662 (1992).
138. Sun, Z. *et al.* Calspermin gene transcription is regulated by two cyclic AMP response elements contained in an alternative promoter in the calmodulin kinase IV gene. *Mol. Cell. Biol.* 15, 561 (1995).
139. Supattapone, S. *et al.* Cyclic AMP-dependent phosphorylation of a brain inositol trisphosphate receptor decreases its release of calcium. *Proc. Natl. Acad. Sci. U. S. A.* 85, 8747 (1988).
140. Swartz, K. J. *et al.* Protein kinase C modulates glutamate receptor inhibition of Ca^{2+} channels and synaptic transmission. *Nature.* 361, 165 (1993).
141. Takai, Y. *et al.* Calcium-dependent activation of a multifunctional protein kinase by membrane phospholipids. *J. Biol. Chem.* 254, 3692 (1979).
142. Tang, W. J. & Gilman, A. G. Type-specific regulation of adenylyl cyclase by G protein beta gamma subunits. *Science.* 254, 1500 (1992).
143. Tang, W. J. *et al.* Expression and characterization of calmodulin-activated (type I) adenylyl cyclase. *J. Biol. Chem.* 266, 8595 (1991).
144. Tauchi, T. *et al.* The ubiquitously expressed Syp phosphatase interacts with c-kit and Grb2 in hematopoietic cells. *J. Biol. Chem.* 269, 25206 (1994).
145. Taussig, R. *et al.* Inhibition of adenylyl cyclase by Gi alpha. *Science.* 261, 218 (1993).
146. Tingley, W. G. *et al.* Regulation of NMDA receptor phosphorylation by alternative splicing of the C-terminal domain. *Nature.* 364, 70 (1993).
147. Torres, J. *et al.* Phosphorylation-regulated cleavage of the tumor suppressor PTEN by caspase-3: implications for the control of protein stability and PTEN-protein interactions. *J. Biol. Chem.* 278, 30652 (2003).
148. Usachev, Y. M. *et al.* Bradykinin and ATP accelerate Ca^{2+} efflux from rat sensory neurons via protein kinase C and the plasma membrane Ca^{2+} pump isoform 4. *Neuron.* 33, 113 (2002).
149. van Houten, M. *et al.* Insulin binding sites localized to nerve terminals in rat median eminence and arcuate nucleus. *Science.* 207, 1081 (1980).
150. van Koppen, C. J. *et al.* Isolation, sequence and functional expression of the mouse m4 muscarinic acetylcholine receptor gene. *Biochim. Biophys. Acta.* 1173, 342 (1993).
151. Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. *Nature Rev. Cancer.* 2, 489 (2002).

152. Wadzinski, B. E. *et al.* Nuclear protein phosphatase 2A dephosphorylates protein kinase A-phosphorylated CREB and regulates CREB transcriptional stimulation. *Mol. Cell. Biol.* 13, 2822 (1993).
153. Wang, L. Y. *et al.* Regulation of NMDA receptors in cultured hippocampal neurons by protein phosphatases 1 and 2A. *Nature.* 369, 230 (1994).
154. Watterson, D. M. *et al.* The complete amino acid sequence of the Ca^{2+} -dependent modulator protein (calmodulin) of bovine brain. *J. Biol. Chem.* 255, 962 (1980).
155. Wei, W. *et al.* The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. *Cancer. Cell.* 8, 25 (2005).
156. Welham, M. J. *et al.* Interleukin (IL)-3 and granulocyte/macrophage colony-stimulating factor, but not IL-4, induce tyrosine phosphorylation, activation, and association of SHPTP2 with Grb2 and phosphatidylinositol 3'-kinase. *J. Biol. Chem.* 269, 23764 (1994).
157. Westenbroek, R. E. *et al.* Biochemical properties and subcellular distribution of an N-type calcium channel α 1 subunit. *Neuron.* 9, 1099 (1993).
158. Westphal, R. S. *et al.* A signaling complex of Ca^{2+} -calmodulin-dependent protein kinase IV and protein phosphatase 2A. *Science.* 280, 1258 (1998).
159. Whitman, M. *et al.* Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. *Nature.* 332, 644 (1988).
160. Wu, L. *et al.* Dual regulation of voltage-gated calcium channels by $\text{PtdIns}(4,5)\text{P}_2$. *Nature.* 419, 947 (2002).
161. Xia, Z. *et al.* Type I calmodulin-sensitive adenylyl cyclase is neural specific. *J. Neurochem.* 60, 305 (1993).
162. Xing, J. *et al.* Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. *Science.* 273, 959 (1996).
163. Xu, N. *et al.* The PH domain of Ras-GAP is sufficient for in vitro binding to beta gamma subunits of heterotrimeric G proteins. *Cell. Mol. Neurobiol.* 16, 51 (1996).
164. Yabana, N. & Shibuya, M. Adaptor protein APS binds the NH2-terminal autoinhibitory domain of guanine nucleotide exchange factor Vav3 and augments its activity. *Oncogene.* 21, 7720 (2002).
165. Yamada, M. *et al.* Insulin receptor substrate (IRS)-1 and IRS-2 are tyrosine-phosphorylated and associated with phosphatidylinositol 3-kinase in response to brain-derived neurotrophic factor in cultured cerebral cortical neurons. *J. Biol. Chem.* 272, 30334 (1997).
166. Yamaguchi, A. *et al.* Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptional activity of p53. *J. Biol. Chem.* 276, 5256 (2001).

167. Yamanashi, Y. & Baltimore, D. Identification of the Abl- and rasGAP-associated 62 kDa protein as a docking protein, *Dok. Cell.* 88, 205 (1997).
168. Yan, Z. & Surmeier, D. J. Muscarinic (m2/m4) receptors reduce N- and P-type Ca^{2+} currents in rat neostriatal cholinergic interneurons through a fast, membrane-delimited, G-protein pathway. *J. Neurosci.* 16, 2592 (1996).
169. Yang, M. *et al.* Requirement of Gbetagamma and c-Src in D2 dopamine receptor-mediated nuclear factor-kappaB activation. *Mol. Pharmacol.* 64, 447 (2003).
170. Yano, S. *et al.* Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway. *Nature.* 396, 584 (1999).
171. Ye, Z. S. & Baltimore, D. Binding of Vav to Grb2 through dimerization of Src homology 3 domains. *Proc. Natl. Acad. Sci. U. S. A.* 91, 12629 (1995).
172. Yokouchi, M. *et al.* APS, an adaptor protein containing PH and SH2 domains, is associated with the PDGF receptor and c-Cbl and inhibits PDGF-induced mitogenesis. *Oncogene.* 18, 759 (1999).
173. Yokoyama, C. T. *et al.* Phosphorylation of the synaptic protein interaction site on N-type calcium channels inhibits interactions with SNARE proteins. *J. Neurosci.* 17, 6929 (1997).
174. Yoshimura, M. & Cooper, D. M. Type-specific stimulation of adenylylcyclase by protein kinase C. *J. Biol. Chem.* 268, 4604 (1993).
175. Yue, Y. *et al.* Ras GTPase-activating protein binds to Akt and is required for its activation. *J. Biol. Chem.* 279, 12883 (2004).
176. Zamanillo, D. *et al.* Identification of a cyclic adenosine 3',5'-monophosphate-dependent protein kinase phosphorylation site in the carboxy terminal tail of human D1 dopamine receptor. *Neurosci. Lett.* 188, 183 (1995).
177. Zylinska, L. *et al.* Protein kinases A and C phosphorylate purified Ca^{2+} -ATPase from rat cortex, cerebellum and hippocampus. *Biochim. Biophys. Acta.* 1448, 99 (1999).